Trial reportAmerican journal of physiology. Lung cellular and molecular physiology2014
Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1.
Trial report in American journal of physiology. Lung cellular and molecular physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Trial
- Proresolving Lipid Mediators in the Respiratory System.Annual review of physiology · 2025Review
- Protective Effects of 7S,15R-Dihydroxy-16S,17S-Epoxy-Docosapentaenoic Acid (diHEP-DPA) against Blue Light-Induced Retinal Damages in A2E-Laden ARPE-19 Cells.Antioxidants (Basel, Switzerland) · 2024Article
- Immunomodulation of periodontitis with SPMs.Frontiers in oral health · 2023Review
- Article
- Article
- Resolvin D1, therapeutic target in acute respiratory distress syndrome.European journal of pharmacology · 2021Review
- Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Animal Models ofInternational journal of molecular sciences · 2019Review
- Nonhuman primate species as models of human bacterial sepsis.Lab animal · 2019Review
- Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?Current gastroenterology reports · 2018Review
- Carbon monoxide in lung cell physiology and disease.American journal of physiology. Cell physiology · 2018Review
- Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.Molecular aspects of medicine · 2017Review
- 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.The American journal of pathology · 2017Review
- Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Review
- Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators.Current opinion in clinical nutrition and metabolic care · 2017Review
- Pro-Resolving Molecules-New Approaches to Treat Sepsis?International journal of molecular sciences · 2017Review
- Immune resolution mechanisms in inflammatory arthritis.Nature reviews. Rheumatology · 2017Review
- Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes.Critical care medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Polymorphonuclear leukocyte (PMN)-mediated acute lung injury from ischemia/reperfusion (I/R) remains a major cause of morbidity and mortality in critical care medicine. Here, we report that inhaled low-dose carbon monoxide (CO) and intravenous resolvin D1 (RvD1) in mice each reduced PMN-mediated acute lung injury from I/R. Inhaled CO (125-250 ppm) and RvD1 (250-500 ng) each reduced PMN lung infiltration and gave additive lung protection. In mouse whole blood, CO and RvD1 attenuated PMN-platelet aggregates, reducing leukotrienes (LTs) and thromboxane B2 (TxB2) in I/R lungs. With human whole blood, CO (125-250 ppm) decreased PMN-platelet aggregates, expression of adhesion molecules, and cysteinyl LTs, as well as TxB2. RvD1 (1-100 nM) also dose dependently reduced platelet activating factor-stimulated PMN-platelet aggregates in human whole blood. In nonhuman primate (baboon) lung infection with Streptococcus pneumoniae, inhaled CO reduced urinary cysteinyl LTs. These results demonstrate lung protection by low-dose inhaled CO as well as RvD1 that each reduced PMN-mediated acute tissue injury, PMN-platelet interactions, and production of both cysteinyl LTs and TxB2. Together they suggest a potential therapeutic role of low-dose inhaled CO in organ protection, as demonstrated using mouse I/R-initiated lung injury, baboon infections, and human whole blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.